To comprehend the current status of new drug development in China,this article examines the new drug applications(NDAs)approved by the National Medical Products Administration(NMPA)in 2023.The analysis is conducted based on drug category,therapeutic area,target,and priority review and approval,providing a valuable reference for researchers in fields related to pharmaceutical innovation.As of December 31,2023,the NMPA had approved a total of 190 NDAs,comprising 117 chemical drugs,64 biological products,and 9 traditional Chinese medicines.Among these,37 were categorized as new drugs in Class 1,and 117 were improved new drugs.Notably,anti-tumor drugs maintained a dominant position,accounting for 34.2％of the total approvals.Furthermore,there was a significant increase in approvals for pediatric drugs and drugs targeting rare diseases.
drug approvalclass 1 innovative drugmodified new drugbiological productstherapeutic usestarget
万方数据
维普
